Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Nanobac Pharmaceuticals, Incorporated is dedicated to advancing human health through the creation and refinement of products and services designed for the identification and management of calcifying nanoparticles (CNPs). The company's offerings include the production and sale of in vitro diagnostic (IVD) kits, which encompass assays, antibodies, and reagents specifically developed for detecting CNPs. Notably, their diagnostic assays include NANO-CAPTURE and NANO-SERO. Furthermore, Nanobac engages in research and clinical studies focused on various urological diseases—such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases—as well as cardiovascular ailments. Established in 1994 and headquartered in Tampa, Florida, the company operated as HealthCentrics Inc. until its name change to Nanobac Pharmaceuticals, Incorporated in December 2002.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.